Area of research
Pathology and Forensic Medicine · Genetics
Research interest
Research interests include Medicine, Internal medicine, Obinutuzumab, Follicular lymphoma, Rituximab, and Adverse effect.
Obinutuzumab Versus Rituximab Immunochemotherapy in Previously Untreated iNHL: Final Results From the GALLIUM Study
Minimal Residual Disease Status Predicts Outcome in Patients With Previously Untreated Follicular Lymphoma: A Prospective Analysis of the Phase III GALLIUM Study
Obinutuzumab-atezolizumab-lenalidomide for the treatment of patients with relapsed/refractory follicular lymphoma: final analysis of a Phase Ib/II trial
Efficacy and safety of obinutuzumab for the first-line treatment of follicular lymphoma: a subgroup analysis of Chinese patients enrolled in the phase III GALLIUM study
An <i>EZH2</i> Gene Expression Signature Is Predictive of Differential Efficacy of Chemotherapy Irrespective of <i>EZH2</i> Mutation Status in Patients with Follicular Lymphoma Treated within the Gallium Trial
Obinutuzumab-Based Immunochemotherapy Prolongs Progression-Free Survival and Time to Next Anti-Lymphoma Treatment in Patients with Previously Untreated Follicular Lymphoma: Four-Year Results from the Phase III GALLIUM Study